Medindia

X

Icon Bioscience Initiates Phase 2/3 Pivotal Clinical Study of Novel Ophthalmic Drug Candidate

Tuesday, January 5, 2010 Research News J E 4
Advertisement
-Trial to Examine Novel Anti-Inflammatory Product in Cataract Surgery Patients

Contact:  Icon Bioscience, Inc.

William S. (Sandy) White

Phone:  408-734-8188   Ext. 14

Email:  sandywhite@iconbioscience.com

Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Derma Sciences Signs Three-Year Contract With Lead...
S
VIVUS to Present at the 2010 JP Morgan Healthcare ...